Physician profile
Bashar Saad
NPI 1275611360
$123,118.92
in general payments reported to CMS, 2019-2025
63 companies · $8,361 in 2025
The $8,361 reported for 2025 was more than what 89% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $43K · 2020: $12K · 2021: $17K · 2022: $13K · 2023: $18K · 2024: $12K · 2025: $8,361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $20K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Education: $116 · Travel and Lodging: $6.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $19,693.09 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $18,643.75 |
| Education | $116.44 |
| Travel and Lodging | $6.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $47,809.92 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $23,039.54 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $15,942.30 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $7,975.40 | 2019-2021 | |
| Novo Nordisk INC | $3,469.95 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $3,434.02 | 2019-2025 | Tepezza, Evenity, Prolia |
| Abbott Laboratories | $3,094.35 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Mannkind Corporation | $2,759.31 | 2019-2025 | Afrezza |
| Dexcom, INC. | $2,609.73 | 2019-2025 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $888.96 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $858.99 | 2021-2025 | Gvoke Hypopen, Recorlev, Keveyis |
| Tandem Diabetes Care, INC. | $819.34 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals Lp | $800.36 | 2019-2022 | |
| Antares Pharma, INC. | $666.29 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Recordati_rare_diseases_inc. | $517.27 | 2020-2025 | Isturisa, Signifor Lar |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $513.93 | 2019-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $491.04 | 2021-2025 | |
| Horizon Therapeutics Plc | $470.05 | 2019-2023 | Tepezza |
| Abbvie INC. | $458.62 | 2019-2025 | Synthroid |
| Amarin Pharma, INC. | $451.04 | 2019-2023 | |
| Embecta Corp. | $447.87 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Esperion Therapeutics, INC. | $437.50 | 2021-2025 | Nexletol, Nexlizet |
| Ascendis Pharma Endocrinology INC | $411.17 | 2024-2025 | Yorvipath |
| Madrigal Pharmaceuticals | $371.81 | 2024-2025 | Rezdiffra, Resmetirom |
| Medtronic, INC. | $360.18 | 2021-2025 | Minimed 780g |
| Cequr Corporation | $345.88 | 2023-2024 | Cequr Simplicity |
| Radius Health, INC. | $344.46 | 2019-2025 | |
| Kyowa Kirin, INC. | $335.72 | 2023-2025 | Crysvita |
| Becton, Dickinson and Company | $265.82 | 2019-2022 | |
| Ascensia Diabetes Care US INC. | $250.56 | 2021-2025 | |
| Bigfoot Biomedical INC | $222.45 | 2022 | |
| Stryker Corporation | $161.11 | 2022 | |
| Corcept Therapeutics | $151.32 | 2019-2025 | Korlym |
| Halozyme INC | $151.03 | 2023 | |
| Alexion Pharmaceuticals, INC. | $145.71 | 2021-2024 | Strensiq |
| Tolmar, INC. | $144.82 | 2023-2025 | Jatenzo |
| Ionis Pharmaceuticals, INC. | $144.66 | 2025 | Tryngolza |
| Grt US Holding, INC. | $136.89 | 2022 | |
| Beta Bionics, INC. | $121.27 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ibsa Pharma INC. | $113.56 | 2019-2022 | |
| Sequel Med Tech, LLC | $104.82 | 2025 | Twiist |
| Allergan, INC. | $102.92 | 2020 | |
| Merck Sharp & Dohme LLC | $102.48 | 2019-2023 | Steglatro, Segluromet, Belsomra |
| Lifescan, INC. | $82.92 | 2020-2022 | |
| Lexicon Pharmaceuticals, INC. | $79.75 | 2023-2024 | Inpefa |
| Acella Pharmaceuticals, LLC | $62.40 | 2023-2025 | NP Thyroid 60 |
| Alvogen INC | $61.58 | 2023-2024 | Teriparatide |
| Pfizer INC. | $60.63 | 2019-2024 | |
| Senseonics, Incorporated | $41.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $39.52 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $34.06 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $31.78 | 2019 | |
| Currax Pharmaceuticals LLC | $26.18 | 2022 | |
| Companion Medical, INC. | $25.54 | 2019 | |
| Medtronic Minimed, INC. | $24.38 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $17.12 | 2025 | |
| Vertiflex, INC. | $15.63 | 2019 | |
| Rgh Enterprises LLC | $15.00 | 2025 | |
| Nevro Corp. | $14.57 | 2023 | Senza |
| Shire North American Group INC | $14.34 | 2019 | |
| Echosens North America, INC. | $14.26 | 2023 | Fibroscan |
| Zealand Pharma US, INC. | $12.18 | 2021 | |
| Travere Therapeutics, INC. | $1.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bashar Saad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.